ClinicalTrials.gg
CompletedNCT05517525Updated Jul 19, 2023

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

A Phase 1 interventional study of Brensocatib in Hepatic Impairment, sponsored by Insmed Incorporated. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Brensocatib
  • INS1007
03

In context

Lead sponsor

Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has (BMI) between 18.0 and 35.0 kilogram per square meter (kg/m\^2)

Inclusion Criteria for Participants With Hepatic Impairment:

  • Clinical diagnosis of chronic hepatic disease, as documented in their medical history of underlying hepatic insufficiency with features of cirrhosis and no acute episodes of illness within 30 days prior to screening, and no significant change in disease status from screening to check-in.
  • Hepatic impairment will be classified using the criteria
  • A stable medication regimen, defined as not starting new drug(s) or changing dosage(s) within 30 days prior to study drug administration. Concomitant medications must be approved by the investigator and medical monitor.

Inclusion Criteria for Healthy Matched Control Participants With Normal Hepatic Function:

  • In good health, determined by no findings from medical history, clinical laboratory evaluations, vital signs measurements, 12-lead (ECG), and physical examination at screening or check-in, as assessed by the investigator (or designee).
  • Matched to hepatically impaired participants in age (±10 years), sex, and BMI (±20%).

Exclusion criteria

Exclusion Criteria:

  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy will not be allowed).
  • Positive (HIV) test
  • Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 30 days prior to dosing.
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days prior to dosing.
  • Use of moderate to strong inducers or inhibitors within 14 days prior to check-in.
  • Have previously completed or withdrawn from this study or any other study investigating brensocatib, and have previously received the IMP.

Exclusion Criteria for Participants With Hepatic Impairment:

  • Positive urine drug screen at screening or check-in, unless the result is due to a prescribed medication.
  • History of significant immunologic impairment such as transplantation.
  • Hepatic encephalopathy Grade ≥2 using scoring.

Exclusion Criteria for Healthy Matched Control Participants with Normal Hepatic Function

  • Positive urine drug screen at screening or check-in.
  • Significant history or clinical manifestation of any immunologic, metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • Positive hepatitis panel. Participants whose results are compatible with prior immunization are eligible at the discretion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1: Brensocatib

    Healthy participants with normal hepatic function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with hepatic impairment.

    Drug: Brensocatib

  • Experimental
    Cohort 2: Brensocatib

    Participants with mild hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

  • Experimental
    Cohort 3: Brensocatib

    Participants with moderate hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

  • Experimental
    Cohort 4: Brensocatib

    Participants with severe hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve (AUC)

    Comparison of the pharmacokinetics of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 9

Secondary outcomes

  1. Fraction Unbound (Fu)

    Assessment of the plasma protein binding of brensocatib in participants with varying degrees of hepatic function relative to matched healthy control participants with normal hepatic function.

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 9

  2. Number of Participants who Experienced at Least one Adverse Event (AE)

    Determination of the safety and tolerability of a single dose of brensocatib in participants with hepatic impairment.

    Time frame: From first dose of study drug up to follow up visit (5-7 days after discharge) or early termination (up to Day 17)

07

Study locations

3 sites
  • USA002
    Rialto, California 92377, United States
  • USA003
    Orlando, Florida 32809, United States
  • USA001
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jun 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Oct 4, 2022
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 1, 2023
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05517525
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Oct 4, 2022
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Last update
Jul 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion